US Drug Recall Register
Class II · Moderate risk Ongoing Initiated Feb 28, 2025 (2 years ago)

Duloxetine Delayed-Release Capsules

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

What was recalled

Duloxetine Delayed-Release Capsules, USP, 20mg, Rx Only, 500-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-746-05

Recalling firm
Breckenridge Pharmaceutical, Inc.
NDC code
51991-746-05
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0271-2025

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Duloxetine recalls

See all
Class II · Moderate risk Ongoing

Duloxetine D/R

Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Direct Rx NDC 61919-482-30 D-0617-2026
Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules

Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Breckenridge Pharmaceutical, Inc. NDC 51991-748-90 D-0583-2026
Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules

Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Breckenridge Pharmaceutical, Inc. NDC 51991-747-10 D-0582-2026
Class II · Moderate risk Ongoing

Duloxetine DR Capsules

Reason CGMP Deviations; presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the FDA acceptable intake limit.

Asclemed USA Inc. NDC 76420-634-30 D-0555-2026
Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules

Reason CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.

Ajanta Pharma Ltd. NDC 27241-097-06 D-0516-2026